Charles Elliott Sigal serves as Executive at Adaptimmune Therapeutics PLC, where they oversee executive responsibilities. Since joining the company, Charles Elliott Sigal has executed 14 insider transactions totaling $338.4K, demonstrating a bullish approach to their equity position. Their most recent transaction on May 30, 2024 involved receiving (via award) 8,000 shares valued at $0.
Charles Elliott Sigal currently holds 23,806 shares of Adaptimmune Therapeutics PLC (ADAP), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Charles Elliott Sigal has been a net buyer of ADAP stock. They have purchased $338.4K and sold $0 worth of shares.
Charles Elliott Sigal's most recent insider trade was on May 30, 2024, when they sold 8,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| May 22, 2023 | VIR | $0 | Award | 6,027 | $N/A | Discretionary |
| Mar 1, 2023 | VIR | $56.8K | Purchase | 2,500 | $22.73 | Discretionary |
| Jan 5, 2023 | VIR | $62.4K | Purchase | 2,500 | $24.96 | Discretionary |
| Jan 4, 2023 | VIR | $63.1K | Purchase | 2,500 | $25.25 | Discretionary |
| Jan 3, 2023 | VIR | $64.0K | Purchase | 2,500 | $25.60 | Discretionary |
| May 23, 2022 | VIR | $0 | Award | 6,405 | $N/A | Discretionary |
| May 21, 2021 | VIR | $0 | Award | 3,374 | $N/A | Discretionary |
| Apr 23, 2018 | SURF | $0 | Conversion | 45,453 | $N/A | Discretionary |
| May 19, 2016 | ADAP | $23.4K | Purchase | 15,000 | $1.56 | Discretionary |
| May 18, 2016 | ADAP | $23.3K | Purchase | 15,000 | $1.55 | Discretionary |
| May 17, 2016 | ADAP | $22.9K | Purchase | 15,000 | $1.53 | Discretionary |
| May 16, 2016 | ADAP | $22.5K | Purchase | 15,000 | $1.50 | Discretionary |